AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of AstraZeneca PLC (LON:AZN) have been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is GBX 7,542.80 ($95.45).

A number of research analysts have recently weighed in on the company. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Thursday, November 7th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 140 ($1.77) target price on shares of AstraZeneca in a research note on Monday, January 27th.

AstraZeneca Stock Up 1.0 %

Shares of AstraZeneca stock opened at £117.08 ($148.17) on Monday. The stock’s fifty day moving average is £109.99 and its 200-day moving average is £114.55. The firm has a market capitalization of £225.27 billion, a PE ratio of 32.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83. AstraZeneca has a 12-month low of GBX 9,670 ($122.37) and a 12-month high of £133.88 ($169.43).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.